Global Pneumococcal Vaccine
Market Report
2025
Pneumococcal Vaccine Market Report 2025 (Global Edition)
The global Pneumococcal Vaccines Market size will be USD 8261.9 million in 2025. Growing incidence of antimicrobial resistance (AMR) encouraging vaccination, which is expected to boost sales to USD 14195.48 million by 2033, with a Compound Annual Growth Rate (CAGR) of 7.00% from 2025 to 2033.
The base year for the calculation is 2024. The historical will be 2021 to 2024. The year 2025 will be estimated one while the forecasted data will be from year 2025 to 2033. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
|
Rating: 4.8 | Review: 11
Share your contact details to receive free updated sample copy/pages of the recently published edition of Pneumococcal Vaccine Market Report 2025.
Global Pneumococcal Vaccine Market Report 2025 Market Size Split by Product Type Outlook: (Synflorix, Pediatric, Adult, Prevenar-13, Pediatric, Adult, PCV 13 (pipeline), Pediatric, Adult, V114 (Merck)...
According to Cognitive Market Research, the global Pneumococcal Vaccines Market size will be USD 8261.9 million in 2025. It will expand at a compound annual growth rate (CAGR) of 7.00% from 2025 to 2033.
- North America held the major market share for more than 40% of the global revenue with a market size of USD 3056.90 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.5% from 2025 to 2033.
- Europe accounted for a market share of over 30% of the global revenue with a market size of USD 2395.95 million.
- APAC held a market share of around 23% of the global revenue with a market size of USD 1982.86 million in 2025 and will grow at a compound annual growth rate (CAGR) of 9.7% from 2025 to 2033.
- South America has a market share of more than 5% of the global revenue with a market size of USD 313.95 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2033.
- The Middle East had a market share of around 2% of the global revenue and was estimated at a market size of USD 330.48 million in 2025. and will grow at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2033.
- Africa had a market share of around 1% of the global revenue and was estimated at a market size of USD 181.76 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.3% from 2025 to 2033.
- Synflorix category is the fastest growing segment of the Pneumococcal Vaccines Market
| 2024 | 2025 | 2032 | 2033 | CAGR | |
|---|---|---|---|---|---|
| Global Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 8261.9 Million | 121212 | $ 14195.5 Million | 7% |
| North America Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 3056.9 Million | 121212 | $ 4684.5 Million | 5.5% |
| United States Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 2411.9 Million | 121212 | 121212 | 5.3% |
| Mexico Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 278.18 Million | 121212 | 121212 | 6% |
| Canada Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 366.83 Million | 121212 | 121212 | 6.3% |
| Europe Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 2395.95 Million | 121212 | $ 3832.8 Million | 6% |
| Switzerland Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 35.94 Million | 121212 | 121212 | 5.7% |
| Italy Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 206.05 Million | 121212 | 121212 | 5.4% |
| Denmark Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 50.31 Million | 121212 | 121212 | 5.8% |
| Germany Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 474.4 Million | 121212 | 121212 | 6.2% |
| Sweden Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 74.27 Million | 121212 | 121212 | 6.1% |
| France Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 220.43 Million | 121212 | 121212 | 5.2% |
| Luxembourg Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 28.75 Million | 121212 | 121212 | 6.3% |
| Spain Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 196.47 Million | 121212 | 121212 | 5.1% |
| United Kingdom Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 402.52 Million | 121212 | 121212 | 6.8% |
| Russia Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 371.37 Million | 121212 | 121212 | 5% |
| Rest of Europe Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 335.43 Million | 121212 | 121212 | 4.7% |
| Asia Pacific Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 1982.86 Million | 121212 | $ 4166.4 Million | 9.7% |
| Singapore Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 39.66 Million | 121212 | 121212 | 10% |
| China Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 832.8 Million | 121212 | 121212 | 9.2% |
| Australia Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 103.11 Million | 121212 | 121212 | 9% |
| South East Asia Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 130.87 Million | 121212 | 121212 | 10.5% |
| India Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 198.29 Million | 121212 | 121212 | 11.6% |
| Taiwan Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 77.33 Million | 121212 | 121212 | 9.5% |
| South Korea Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 237.94 Million | 121212 | 121212 | 8.8% |
| Japan Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 273.63 Million | 121212 | 121212 | 8.2% |
| Rest of APAC Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 89.23 Million | 121212 | 121212 | 9.5% |
| South America Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 313.95 Million | 121212 | $ 567.8 Million | 7.7% |
| Peru Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 25.74 Million | 121212 | 121212 | 7.9% |
| Colombia Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 27.94 Million | 121212 | 121212 | 7.5% |
| Argentina Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 52.74 Million | 121212 | 121212 | 8.6% |
| Brazil Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 134.37 Million | 121212 | 121212 | 8.3% |
| Chile Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 22.6 Million | 121212 | 121212 | 8% |
| Rest of South America Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 50.55 Million | 121212 | 121212 | 6.8% |
| Middle East Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 330.48 Million | 121212 | $ 624.6 Million | 8.3% |
| UAE Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 68.08 Million | 121212 | 121212 | 8.8% |
| Turkey Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 26.44 Million | 121212 | 121212 | 8.9% |
| Qatar Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 26.44 Million | 121212 | 121212 | 7.8% |
| Saudi Arabia Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 116.33 Million | 121212 | 121212 | 8.6% |
| Egypt Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 19.83 Million | 121212 | 121212 | 8.1% |
| Rest of Middle East Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 73.37 Million | 121212 | 121212 | 7.5% |
| Africa Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 181.76 Million | 121212 | $ 319.4 Million | 7.3% |
| South Africa Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 63.98 Million | 121212 | 121212 | 8.2% |
| Nigeria Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 14.54 Million | 121212 | 121212 | 7.5% |
| Rest of Africa Pneumococcal Vaccine Market Sales Revenue | 121212 | $ 103.24 Million | 121212 | 121212 | 6.5% |
| Base Year | 2024 |
| Historical Data Time Period | 2021-2024 |
| Forecast Period | 2025-2033 |
| Market Split by Product Type Outlook: |
|
| Market Split by Distribution Channel Outlook: |
|
| Market Split by Sector Outlook: |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Market Drivers:
| |
Market Restrains:
| |
Market Trends:
| |
Report scope is customizable as we have a huge database of Pneumococcal Vaccine industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Pneumococcal Vaccine Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Pneumococcal Vaccine Market Report Description
Introduction of the Pneumococcal Vaccines Market
The market for pneumococcal vaccinations is centred on those that are intended to guard against infections brought on by Streptococcus pneumoniae, a bacterium that causes meningitis, pneumonia, and septicemia. Particularly in newborns, older people, and immunocompromised people, these vaccinations, such as pneumococcal conjugate vaccines (PCVs) and pneumococcal polysaccharide vaccines (PPSVs), help lower morbidity and mortality. Growing immunization programs, increasing disease prevalence, and developments in next-generation vaccines are the main factors driving market dynamics. However, market expansion is constrained by high vaccine costs, restricted availability in low-income areas, and vaccine reluctance. Global market expansion prospects are presented by growing adult immunization programs, new product advancements, and more government assistance.
In April 2024, Merck announced the findings of the STRIDE-10 phase 3 clinical study, which developed an adult 21-valent pneumococcal conjugate vaccination. https://www.merck.com/news/merck-announces-positive-data-for-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-for-adults/
Pneumococcal Vaccine Market Size
Market Dynamics of Pneumococcal Vaccines Market
Key Drivers for Pneumococcal Vaccines Market
Rising Prevalence of Pneumococcal Infections to Boost Market Growth
The market for pneumococcal vaccines is mostly driven by the increasing incidence of pneumococcal infections. Particularly for young children, the elderly, and patients with weakened immune systems, pneumococcal infections, such as pneumonia, meningitis, and bacteremia, present serious health hazards. The demand for preventative vaccinations has increased as a result of the growing worldwide burden of infectious illnesses. The World Health Organization states that a significant portion of respiratory-related fatalities each year are caused by pneumococcal pneumonia. Governments and healthcare institutions are extensively promoting immunization programs in an effort to stop the spread of these illnesses. Furthermore, the need for efficient vaccination tactics is further highlighted by newly discovered antibiotic-resistant strains of Streptococcus pneumoniae, which is driving global market expansion.
Growing Geriatric Population to Boost Market Growth
The market for pneumococcal vaccines is being driven in large part by the ageing population. The compromised immune systems of the elderly put them at greater risk for serious pneumococcal infections, such as bloodstream infections, meningitis, and pneumonia. The WHO projects that the number of people 65 and older worldwide will quadruple by 2050, which would raise the need for preventative healthcare measures. Numerous governments and healthcare organizations are prioritizing pneumococcal immunization for older individuals in an effort to lower hospitalization and mortality rates. Global market expansion is also aided by the increase in chronic diseases like diabetes and cardiovascular ailments among the elderly, which increases the demand for vaccination.
Restraint Factor for the Pneumococcal Vaccines Market
High Vaccine Costs Will Limit Market Growth
The market for pneumococcal vaccines is still severely constrained by high vaccination costs, which restrict availability, particularly in low- and middle-income nations. Complex research, development, and production processes make advanced pneumococcal vaccines like PCV13, PCV15, and PCV20 costly. The high expense puts a strain on people's finances and healthcare systems, which lowers vaccination rates. Due to financial limitations, many impoverished countries find it difficult to incorporate pneumococcal vaccinations into regular immunization programs. Affordability is still an issue even though WHO, Gavi, and UNICEF initiatives seek to subsidize vaccine prices. This pricing barrier raises the danger of pneumococcal disease outbreaks and hinders mass immunization, which has a considerable impact on market penetration.
Market Trends in Pneumococcal Vaccines Market
Development of Next-Generation Vaccines
The market for pneumococcal vaccinations is mostly driven by the creation of next-generation vaccines. More serotype coverage is provided by emerging vaccines like PCV15 and PCV20, which protect against strains of pneumococcal bacteria that are resistant to antibiotics and are constantly changing. Developments are improving immunogenicity in protein-based and conjugate vaccines, which offer longer-lasting immunity with fewer doses. To produce vaccines more effectively and respond to new mutations, mRNA technology is now being investigated. Prominent pharmaceutical firms are spending money on R&D partnerships in order to spur innovation. These technology advancements are anticipated to greatly increase market growth by improving vaccine efficacy, accessibility, and uptake across a range of age groups, in conjunction with regulatory clearances and expanding immunization programs.
Expanding Adult Vaccination Programs
The market for pneumococcal vaccines is mostly driven by the growth of adult vaccination programs. Pneumococcal vaccination has historically targeted children, but growing knowledge of the disease's effects on adults, particularly the elderly and those with weaker immune systems, is encouraging vaccination uptake. Pneumococcal vaccinations are being incorporated into national immunization schedules for adults by governments and healthcare organizations around the world, especially for people with chronic disorders like diabetes, COPD, and cardiovascular diseases. Demand for vaccines has also increased as a result of the post-pandemic focus on preventing respiratory illnesses. The WHO, CDC, and other health organizations' expanded vaccine recommendations, government financing, and employer-sponsored initiatives are all contributing to the market's rapid expansion.
We have various report editions of Pneumococcal Vaccine Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Competitive Landscape of the Pneumococcal Vaccines Market
The market for pneumococcal vaccines is extremely competitive, with major manufacturers concentrating on research and development, the introduction of new products, and international growth. Prominent corporations include GlaxoSmithKline (Synflorix), Merck & Co., Inc. (Pneumovax, Vaxneuvance), and Pfizer Inc. (Prevnar series). Government partnerships and new biotech companies further heighten competition. To bolster their position in the burgeoning pneumococcal vaccination industry, businesses are investing in next-generation vaccines, reaching a wider audience, and forming strategic alliances.
Vaxcyte completed the phase-2 clinical study in March 2024 to assess the effectiveness of the 24-valent pneumococcal conjugate vaccine (PCV) candidate VAX-24 in eradicating invasive pneumococcal disease (IPD) in children. https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-completes-enrollment-phase-2-study-evaluating-vax-24> In January 2024, The Committee of Medicinal Products Intended for Human Use (CHMP) of the European Medicines Agency (EMA) granted Pfizer Inc. marketing authorization for their 20-valent pneumococcal conjugate vaccine candidate (20vPnC). https://www.pfizer.com/news/announcements/pfizer-receives-positive-chmp-opinion-its-20-valent-pneumococcal-conjugate In October 2023, Lonza and Vaxcyte, Inc. worked together to sign a new commercial manufacturing contract. Vaxcyte intends to increase its commercial manufacturing capability for its PCV candidates with this partnership. https://www.lonza.com/news/2023-10-16-14-00 In April 2023, The FDA approved Pfizer Inc.'s Prevnar 20 to prevent newborns from contracting Invasive Pneumococcal Disease (IPD). https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20r-pfizers-20-valent-pneumococcal
Top Companies Market Share in Pneumococcal Vaccine Industry: (In no particular order of Rank)
- Serum Institute of India Pvt. Ltd.
- CSL
- Sanofi
- GSK plc
- Merck & Co. Inc.
- Pfizer Inc.
- Walvax Biotechnology Co. Ltd
- Beijing Minhai Biotechnology Co. Ltd.
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Regional Analysis of the Pneumococcal Vaccines Market
Which Region Dominates the Pneumococcal Vaccines Market in 2025?
According to Cognitive Market Research, North America currently dominates the Pneumococcal Vaccines Market. North America's high vaccination rates, robust healthcare system, and government backing are expected to propel the expansion of the pneumococcal vaccines market. Widespread awareness efforts and the CDC's recommendations for routine immunizations help to boost vaccine uptake. Demand is also fueled by growing geriatric and immunocompromised populations. Prominent pharmaceutical firms, such as Pfizer and Merck, control the market thanks to their ongoing R&D expenditures in vaccines of the future. Additional factors that increase accessibility include government support, favourable reimbursement procedures, and programs run by groups like WHO and Gavi. North America's emphasis on adult immunization programs and technological developments in vaccines make it a major market driver.
Which Region is Expanding at the Fastest CAGR?
Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). The expansion of the pneumococcal vaccines market is anticipated to be driven by Asia Pacific because of the region's expanding healthcare infrastructure, growing government immunization programs, and rising illness prevalence. Growing awareness and government-led vaccination campaigns are driving up vaccine usage in nations like China, India, and Japan. Furthermore, WHO, Gavi, and UNICEF assistance is increasing vaccine accessibility in underdeveloped countries. The market demand is further fueled by the region's sizable elderly and pediatric population as well as rising disposable income. By making investments in regional production and delivery systems, pharmaceutical corporations are growing their footprint. Asia Pacific's contribution to market expansion is reinforced by the introduction of reasonably priced vaccinations and public-private partnerships.
The current report Scope analyzes Pneumococcal Vaccine Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Pneumococcal Vaccine Market Share (%) by Region (2021-2033)
Pneumococcal Vaccine Market Share (%) by Country
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
North America Pneumococcal Vaccine
According to Cognitive Market Research, the global Pneumococcal Vaccines Market size was estimated at USD 43521.6 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 3056.90 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.5% from 2025 to 2033.
United States Pneumococcal Vaccines Market size is USD 2411.90 million in 2025
According to Cognitive Market Research, the US had a major share in the Pneumococcal Vaccines Market with a market size of USD 2411.90 million in 2025 and is projected to grow at a CAGR of 5.3% during the forecast period. The U.S. High healthcare spending and robust government vaccination programs fuel demand.
Canada Pneumococcal Vaccines Market size is USD 366.83 million in 2025
The Canadian Pneumococcal Vaccines Market had a market share of USD 366.83 million in 2025 and is projected to grow at a CAGR of 6.3% during the forecast period. In Canada, The country's expanding senior population and universal healthcare coverage encourages the use of vaccines.
Mexico Pneumococcal Vaccines Market size is USD 278.18 million in 2025
The Mexico Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 6.0% during the forecast period, with a market size of USD 278.18 million in 2025..
Europe Pneumococcal Vaccine
According to Cognitive Market Research, the global Pneumococcal Vaccines Market size was estimated at USD 8261.9 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 2395.95 million in 2025 and will grow at a compound annual growth rate (CAGR) of 6.0% from 2025 to 2033.
United Kingdom Pneumococcal Vaccines Market size is USD 402.52 million in 2025
The United Kingdom Pneumococcal Vaccines Market had a market share of USD 402.52 million in 2025 and is projected to grow at a CAGR of 6.8% during the forecast period. In the UK, Growing awareness and immunisation programmes supported by the NHS boost market expansion.
France Pneumococcal Vaccines Market size is USD 220.43 million in 2025
The France Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 220.43 million in 2025.
Germany Pneumococcal Vaccines Market size is USD 474.40 million in 2025
According to Cognitive Market Research, the German Pneumococcal Vaccines Market size was valued at USD 474.40 million in 2025 and is projected to grow at a CAGR of 6.2% during the forecast period. In Germany, Growing concerns about antibiotic resistance and sophisticated healthcare infrastructure drive demand.
Italy Pneumococcal Vaccines Market size is USD 206.05 million in 2025
The Italy Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 5.4% during the forecast period, with a market size of USD 206.05 million in 2025.
Russia Pneumococcal Vaccines Market size is USD 371.37 million in 2025
The Russia Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 5.0% during the forecast period, with a market size of USD 371.37 million in 2025
Spain Pneumococcal Vaccines Market size is USD 196.47 million in 2025
The Spain Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 5.1% during the forecast period with a market size of USD 196.47 million in 2025
Sweden Pneumococcal Vaccines Market size is USD 74.27 million in 2025
The Sweden Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 6.1% during the forecast period, with a market size of USD 74.27 million in 2025.
Denmark Pneumococcal Vaccines Market size is USD 50.31 million in 2025
The Denmark Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 5.8% during the forecast period, with a market size of USD 50.31 million in 2025
Switzerland Pneumococcal Vaccines Market size is USD 35.94 million in 2025
The Switzerland Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 35.94 million in 2025.
Luxembourg Pneumococcal Vaccines Market size is USD 28.75 million in 2025
The Luxembourg Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 6.3% during the forecast period, with a market size of USD 28.75 million in 2025.
Rest of Europe Pneumococcal Vaccines Market size is USD 335.43 million in 2025
The Rest of Europe's Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 335.43 million in 2025.
Asia Pacific Pneumococcal Vaccine
According to Cognitive Market Research, the global Pneumococcal Vaccines Market size was estimated at USD 8261.9 Million, out of which APAC held the market share of around 23% of the global revenue with a market size of USD 1982.86 million in 2025 and will grow at a compound annual growth rate (CAGR) of 9.7% from 2025 to 2033.
China Pneumococcal Vaccines Market size is USD 832.80 million in 2025
According to Cognitive Market Research, the China Pneumococcal Vaccines Market size was valued at USD 832.80 million in 2025 and is projected to grow at a CAGR of 9.2% during the forecast period. Pneumococcal Vaccines surged in China due to the Government vaccination requirements and the growing middle-class fuel market expansion.
Japan Pneumococcal Vaccines Market size is USD 273.63 million in 2025
The Japan Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 8.2% during the forecast period, with a market size of USD 273.63 million in 2025
South Korea Pneumococcal Vaccines Market size is USD 237.94 million in 2025
The South Korea Pneumococcal Vaccines Market had a market share of USD 237.94 million in 2025 and is projected to grow at a CAGR of 8.8% during the forecast period..
India Pneumococcal Vaccines Market size is USD 198.29 million in 2025
The Indian Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 11.6% during the forecast period, with a market size of USD 198.29 million in 2025. In India, Demand is driven by growing private sector investments in healthcare and expanding childhood vaccination programs.
Australia Pneumococcal Vaccines Market size is USD 103.11 million in 2025
The Australian Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 9.0% during the forecast period, with a market size of USD 103.11 million in 2025.
Singapore Pneumococcal Vaccines Market size is USD 39.66 million in 2025
The Singapore Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 10.0% during the forecast period, with a market size of USD 39.66 million in 2025.
Taiwan Pneumococcal Vaccines Market size is USD 77.33 million in 2025
The Taiwan Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 9.5% during the forecast period, with a market size of USD 77.33 million in 2025.
South East Asia Pneumococcal Vaccines Market size is USD 130.87 million in 2025
The South East Asia Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 10.5% during the forecast period, with a market size of USD 130.87 million in 2025.
Rest of APAC Pneumococcal Vaccines Market size is USD 89.23 million in 2025
The Rest of APAC Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 9.5% during the forecast period, with a market size of USD 89.23 million in 2025.
South America Pneumococcal Vaccine
According to Cognitive Market Research, the global Pneumococcal Vaccines Market size was estimated at USD 8261.9 Million, out of which South America held the market share of around 5% of the global revenue with a market size of USD 313.95 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2033.
Brazil Pneumococcal Vaccines Market size is USD 134.37 million in 2025
According to Cognitive Market Research, Brazil's Pneumococcal Vaccines Market size was valued at USD 134.37 million in 2025 and is projected to grow at a CAGR of 8.3% during the forecast period. Pneumococcal Vaccines flourished in Brazil due to the increasing prevalence of pneumonia, and government-led immunization initiatives encourage market growth.
Argentina Pneumococcal Vaccines Market size is USD 52.74 million in 2025
Argentina's Pneumococcal Vaccines Market had a market share of USD 52.74 million in 2025 and is projected to grow at a CAGR of 8.6% during the forecast period. Argentina’s Strong pharmaceutical distribution networks and public health regulations encourage the use of vaccines.
Colombia Pneumococcal Vaccines Market size is USD 27.94 million in 2025
Colombia Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 7.5% during the forecast period, with a market size of USD 27.94 million in 2025
Peru Pneumococcal Vaccines Market size is USD 25.74 million in 2025
Peru Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 7.9% during the forecast period, with a market size of USD 25.74 million in 2025.
Chile Pneumococcal Vaccines Market size is USD 22.60 million in 2025
Chile Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 8.0% during the forecast period, with a market size of USD 22.60 million in 2025
Rest of South America Pneumococcal Vaccines Market size is USD 50.55 million in 2025
The Rest of South America's Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 6.8% during the forecast period, with a market size of USD 50.55 million in 2025.
Middle East Pneumococcal Vaccine
According to Cognitive Market Research, the global Pneumococcal Vaccines Market size was estimated at USD 8261.9 Million, out of which the Middle East held the major market share of around 2% of the global revenue with a market size of USD 330.48 million in 2025 and will grow at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2033..
Qatar Pneumococcal Vaccines Market size is USD 26.44 million in 2025
The Qatar Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 7.8% during the forecast period, with a market size of USD 26.44 million in 2025. Pneumococcal Vaccines flourished in Qatar due to the Mandatory vaccinations for expats and a high-income population support demand.
Saudi Arabia Pneumococcal Vaccines Market size is USD 116.33 million in 2025
The Saudi Arabia Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 8.6% during the forecast period, with a market size of USD 116.33 million in 2025.
Turkey Pneumococcal Vaccines Market size is USD 26.44 million in 2025
The Turkey Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 8.9% during the forecast period, with a market size of USD 26.44 million in 2025. Pneumococcal Vaccines sales flourished in Turkey due to Immunization rates being increased by government incentives and the expansion of healthcare services.
UAE Pneumococcal Vaccines Market size is USD 68.08 million in 2025
The UAE Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 8.8% during the forecast period, with a market size of USD 68.08 million in 2025.
Egypt Pneumococcal Vaccines Market size is USD 19.83 million in 2025
The Egypt Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 8.1% during the forecast period, with a market size of USD 19.83 million in 2025.
Rest of the Middle East Pneumococcal Vaccines Market size is USD 73.37 million in 2025
The Rest of the Middle East Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 7.5% during the forecast period, with a market size of USD 73.37 million in 2025
Africa Pneumococcal Vaccine
According to Cognitive Market Research, the global Pneumococcal Vaccines Market size was estimated at USD 8261.9 Million, out of which Africa held the major market share of around 2% of the global revenue with a market size of USD 181.76 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.3% from 2025 to 2033..
Nigeria Pneumococcal Vaccines Market size is USD 14.54 million in 2025
The Nigeria Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 7.5% during the forecast period, with a market size of USD 14.54 million in 2025. Pneumococcal vaccination sales flourish due to the Pneumococcal vaccination uptake is driven by international aid initiatives and efforts to lower child mortality.
South Africa Pneumococcal Vaccines Market size is USD 63.98 million in 2025
The South Africa Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 8.2% during the forecast period, with a market size of USD 63.98 million in 2025.
Rest of Africa Pneumococcal Vaccines Market size is USD 103.24 million in 2025
The Rest of Africa Pneumococcal Vaccines Market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 103.24 million in 2025.
Pneumococcal Vaccine Market Analysis
Global Pneumococcal Vaccine Market Report 2025 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Pneumococcal Vaccine Industry growth. Pneumococcal Vaccine market has been segmented with the help of its Product Type Outlook:, Distribution Channel Outlook: Sector Outlook:, and others. Pneumococcal Vaccine market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
How are Segments Performing in the Global Pneumococcal Vaccines Market?
Pneumococcal Vaccines Market Product Type Segment Analysis
According to Cognitive Market Research, Prevenar-13 is likely to dominate the Pneumococcal Vaccines Market. Because of its comprehensive protection against 13 serotypes of Streptococcus pneumoniae, Pfizer's Prevenar 13 vaccine is in high demand in the pneumococcal vaccines market. National vaccination programs, private healthcare facilities, and high-risk populations like newborns, the elderly, and patients with impaired immune systems all make extensive use of it. Government recommendations, increased disease prevalence, and growing adult immunization programs are the main drivers of demand. Its expanding use is further aided by hospital-based immunization programs, reimbursement regulations, and raised awareness. High demand is seen in developed regions like North America and Europe, while better access to healthcare is driving development in emerging markets.
Synflorix is the fastest-growing segment in the Pneumococcal Vaccines Market. Because it is affordable and included in national immunization programs, Synflorix, a product of GlaxoSmithKline (GSK), is in high demand in the pneumococcal vaccines market, especially in low- and middle-income nations. It is commonly used for pediatric vaccination and offers protection against ten serotypes of Streptococcus pneumoniae. Demand is driven by government-funded immunization programs, assistance from UNICEF, WHO, and Gavi, as well as rising awareness. Africa, Latin America, and Asia Pacific's emerging markets are important locations for expansion. Additionally, its commercial presence is strengthened, particularly in public healthcare systems, by its involvement in lowering incidences of otitis media and childhood pneumonia.
Pneumococcal Vaccine Market Share (%) by Product Type Outlook: in 2021-2033
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Pneumococcal Vaccine Industry. Request a Free Sample PDF!
Pneumococcal Vaccines Market Distribution Channel Segment Analysis
According to Cognitive Market Research, the Public Authorities segment holds the largest share of the market. Because government-led immunization campaigns ensure extensive vaccine accessibility, the public authority distribution channel is essential to the pneumococcal vaccines market. The WHO, Gavi, UNICEF, and national health departments are among the organizations that purchase and distribute vaccines, especially in low- and middle-income nations. The goal of these initiatives is to provide free or heavily discounted vaccinations to high-risk groups, older people, and babies. Pneumococcal disease burden is decreased, and public health outcomes are improved globally by widespread vaccination use, which is fueled by public health campaigns, collaborations with pharmaceutical firms, and support from international health organizations.
In the Pneumococcal Vaccines Market, the Wholesalers (pharmacy channel) segment has been expanding at a rapid pace. In the pneumococcal vaccine market, wholesalers (pharmacy channels) play a crucial role in ensuring that vaccinations are effectively distributed to hospitals, clinics, retail pharmacies, and healthcare practitioners. Vaccines are bought in bulk from producers by pharmaceutical wholesalers, who then distribute them via vast supply systems. The pneumococcal vaccination is now more widely available outside of hospitals because of retail pharmacies and specialist drug stores that provide it to adults, the elderly, and high-risk persons. This channel is essential in developed nations where pharmacy-based immunization programs and private healthcare services are expanding. Collaborations between wholesalers and vaccine producers improve distribution effectiveness and guarantee timely vaccination supply to satisfy public health needs.
Pneumococcal Vaccine Market Share (%) by Distribution Channel Outlook: in 2021-2033
2021
2025
2033
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Pneumococcal Vaccine Sector Outlook: Segment Analysis
Pneumococcal Vaccines Market Sector Segment Analysis
According to Cognitive Market Research, The Public segment holds the largest market share. Significant demand for pneumococcal vaccines is driven by the public sector, mainly through national healthcare initiatives, government vaccination programs, and international health organizations like UNICEF, WHO, and Gavi. Pneumococcal vaccinations are incorporated into regular immunization schedules in many nations to protect high-risk groups, older people, and babies. Accessibility is increased, especially in low- and middle-income areas, by providing free or heavily discounted vaccinations through public hospitals, community clinics, and healthcare facilities. Government support, large-scale vaccination purchases, and multinational partnerships all increase demand, which lowers healthcare expenses, lowers the prevalence of disease, and enhances global public health outcomes.
In the Pneumococcal Vaccines market, the rapidly growing sector is the Private category. The demand for pneumococcal vaccines is largely driven by the private sector, especially in industrialized areas with sophisticated healthcare systems. Outside government programs, adults, seniors, and high-risk persons can obtain immunizations from hospitals, private clinics, pharmacies, and corporate healthcare programs. Employer-sponsored immunization programs and growing public awareness of preventative healthcare also increase demand. Furthermore, more private-sector adoption is facilitated by customized healthcare services and high-end vaccinations. The demand for self-paid vaccinations is increasing because of rising disposable incomes and better access to healthcare, particularly in urban areas of North America, Europe, and Asia Pacific.
- Public
- Private
Author's Detail
Anushka GoreResearch Associate at Cognitive Market Research
Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.
Bio :
Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the medical devices & consumables industry. She has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services. Her expertise in Market Research and business intelligence has equipped her with the skills necessary to analyze complex information and provide strategic recommendations.
In her current role, Anushka is a highly motivated and detail-oriented research analyst with a passion for uncovering valuable insights from data. She thrives in dynamic environments where her analytical abilities and research expertise can contribute to informed decision-making for businesses. Her collaborative approach facilitated effective communication of insights, fostering a data-driven culture within the organization.Anushka remains an invaluable asset in the dynamic landscape of market research.
Author's Conclusion
Conclusion
- The global Pneumococcal Vaccines Market will expand significantly by 7.00% CAGR between 2025 and 2033.
- Prevenar-13 is expected to dominate the Pneumococcal Vaccines Market over the forecast period. Government immunization programs, increased illness awareness, and widespread protection are the main factors driving demand for Prevenar 13. High use among immunocompromised patients, the elderly, and babies propels market expansion, particularly in developed and emerging markets.
- Public holds the largest market share in the Sector segment. The public sector ensures universal access for newborns, older people, and high-risk groups, especially in developing nations, by driving demand through government immunization programs, WHO and Gavi support, and free or subsidized immunizations.
Frequently Asked Questions (FAQs)
The global market size for Pneumococcal Vaccines in 2025 is USD 8261.9 million.
The global Pneumococcal Vaccines Market is expected to grow with a CAGR of 7.00% over the projected period.
North America held a significant global Pneumococcal Vaccines Market revenue share in 2025.
Asia-Pacific will witness the fastest growth of the global Pneumococcal Vaccines Market over the coming years.
The US had the most significant global Pneumococcal Vaccines Market revenue share in 2025.
The main driver of the growth of the Pneumococcal Vaccines Market is the higher demand for immunization in war-torn and refugee-affected regions and the Increased use of AI and big data in vaccine distribution and monitoring.
The Public Authorities category dominates the market.
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Pneumococcal Vaccine Market
According to Merck, the FDA in the US has authorized its next-generation vaccine to guard against pneumococcal illness in adults. Pneumonia can result from infections caused by the illness in the lungs, among other sections of the body. The bacterium that may cause such diseases comes in around a hundred different types. In a range of adult populations across trials, Merck's vaccine, marketed under the trade name Capvaxive, assisted in eliciting an immune response against all 21 serotypes, or varieties of the bacterium, that the injection targeted. The vaccine costs USD 287 a dose at wholesale, according to the drugmaker, but most people will probably be able to get it for free if the advisors at the Centres for Disease Control and Prevention routinely suggest it. Currently, Merck offers two authorized pneumococcal vaccinations: Pneumovax 23 for people 50 years of age and above, as well as Vaxneuvance for those six weeks of age and older who are at an increased risk of contracting the illness.
Source Link: https://health.economictimes.indiatimes.com/news/pharma/drug-approvals-launches/us-fda-approves-mercks-pneumococcal-vaccine-for-adults/111070701?utm_source=top_news&utm_medium=sectionListing
Sources from Medical Devices & Consumables Industry
- http://www.trade.gov
- http://www.gov.uk
- http://www.fda.gov
- http://www.hhs.gov
- http://www.who.int
- http://www.bls.gov
- http://www.gao.gov
- http://www.ncbi.nlm.nih.gov
- http://www.healthcaredive.com
- http://www.weforum.org
- http://www.health.gov.za
- http://www.usaid.gov
- http://www.eumdr.com
- http://www.cdc.gov
- http://www.ama-assn.org
- http://www.washingtonpost.com
- http://www.ecfr.gov
- http://www.hbr.org
- http://www.worldbank.org
- http://www.commission.europa.eu
- http://www.cbi.eu
- http://www.unicef.org
- http://www.ecipe.org
- http://www.ema.europa.eu
Pneumococcal Vaccine Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Product Type Outlook: | Synflorix, Pediatric, Adult, Prevenar-13, Pediatric, Adult, PCV 13 (pipeline), Pediatric, Adult, V114 (Merck), Pediatric, Adult, PCV-20 (Pfizer), Pediatric, Adult, PCV-10 (SII), Pediatric, Adult, PPSV-23, Pediatric, Adult |
| Distribution Channel Outlook: | Wholesalers (pharmacy channel), Specialized Companies, Public Authorities, Others |
| Sector Outlook: | Public, Private |
| List of Competitors | Serum Institute of India Pvt. Ltd., CSL, Sanofi, GSK plc, Merck & Co. Inc., Pfizer Inc., Walvax Biotechnology Co. Ltd, Beijing Minhai Biotechnology Co. Ltd. |
Expand All
This chapter will help you gain GLOBAL Market Analysis of Pneumococcal Vaccine. Further deep in this chapter, you will be able to review Global Pneumococcal Vaccine Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Pneumococcal Vaccine Revenue Market Size, Trend Analysis 2021 - 2033
-
1.2 Global Pneumococcal Vaccine Market Size By Regions 2021 - 2033
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Pneumococcal Vaccine Revenue Market Size By Region
-
-
1.3 Global Pneumococcal Vaccine Market Size By Product Type Outlook: 2021 - 2033
-
1.3.1 Synflorix Market Size
-
1.3.2 Pediatric Market Size
-
1.3.3 Adult Market Size
-
1.3.4 Prevenar-13 Market Size
-
1.3.5 Pediatric Market Size
-
1.3.6 Adult Market Size
-
1.3.7 PCV 13 (pipeline) Market Size
-
1.3.8 Pediatric Market Size
-
1.3.9 Adult Market Size
-
1.3.10 V114 (Merck) Market Size
-
1.3.11 Pediatric Market Size
-
1.3.12 Adult Market Size
-
1.3.13 PCV-20 (Pfizer) Market Size
-
1.3.14 Pediatric Market Size
-
1.3.15 Adult Market Size
-
1.3.16 PCV-10 (SII) Market Size
-
1.3.17 Pediatric Market Size
-
1.3.18 Adult Market Size
-
1.3.19 PPSV-23 Market Size
-
1.3.20 Pediatric Market Size
-
1.3.21 Adult Market Size
-
-
1.4 Global Pneumococcal Vaccine Market Size By Distribution Channel Outlook: 2021 - 2033
-
1.4.1 Wholesalers (pharmacy channel) Market Size
-
1.4.2 Specialized Companies Market Size
-
1.4.3 Public Authorities Market Size
-
1.4.4 Others Market Size
-
-
1.5 Global Pneumococcal Vaccine Market Size By Sector Outlook: 2021 - 2033
-
1.5.1 Public Market Size
-
1.5.2 Private Market Size
-
-
1.6 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.7 Executive Summary Global Market (2021 vs 2025 vs 2033)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.7.1 Regional Market Revenue Summary 2021 vs 2025 vs 2033
-
1.7.2 Global Market Revenue Split By Product Type Outlook:
-
1.7.3 Global Market Revenue Split By Distribution Channel Outlook:
-
1.7.4 Global Market Revenue Split By Sector Outlook:
-
1.7.5 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
This chapter will help you gain North America Market Analysis of Pneumococcal Vaccine. Further deep in this chapter, you will be able to review North America Pneumococcal Vaccine Market Split by various segments and Country Split.
Chapter 2 North America Market Analysis
-
2.1 North America Pneumococcal Vaccine Market Size 2021 - 2033
-
2.1.1 North America Pneumococcal Vaccine Market Size By Country 2021 - 2033
-
2.1.2 North America Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
2.1.2.1 North America Synflorix Market Size
-
2.1.2.2 North America Pediatric Market Size
-
2.1.2.3 North America Adult Market Size
-
2.1.2.4 North America Prevenar-13 Market Size
-
2.1.2.5 North America Pediatric Market Size
-
2.1.2.6 North America Adult Market Size
-
2.1.2.7 North America PCV 13 (pipeline) Market Size
-
2.1.2.8 North America Pediatric Market Size
-
2.1.2.9 North America Adult Market Size
-
2.1.2.10 North America V114 (Merck) Market Size
-
2.1.2.11 North America Pediatric Market Size
-
2.1.2.12 North America Adult Market Size
-
2.1.2.13 North America PCV-20 (Pfizer) Market Size
-
2.1.2.14 North America Pediatric Market Size
-
2.1.2.15 North America Adult Market Size
-
2.1.2.16 North America PCV-10 (SII) Market Size
-
2.1.2.17 North America Pediatric Market Size
-
2.1.2.18 North America Adult Market Size
-
2.1.2.19 North America PPSV-23 Market Size
-
2.1.2.20 North America Pediatric Market Size
-
2.1.2.21 North America Adult Market Size
-
-
2.1.3 North America Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
2.1.3.1 North America Wholesalers (pharmacy channel) Market Size
-
2.1.3.2 North America Specialized Companies Market Size
-
2.1.3.3 North America Public Authorities Market Size
-
2.1.3.4 North America Others Market Size
-
-
2.1.4 North America Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
2.1.4.1 North America Public Market Size
-
2.1.4.2 North America Private Market Size
-
-
-
2.2 United States Market Size 2021 - 2033
-
2.2.1 United States Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
2.2.2 United States Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
2.2.3 United States Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
2.3 Canada Market Size 2021 - 2033
-
2.3.1 Canada Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
2.3.2 Canada Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
2.3.3 Canada Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
2.4 Mexico Market Size 2021 - 2033
-
2.4.1 Mexico Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
2.4.2 Mexico Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
2.4.3 Mexico Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
This chapter will help you gain Europe Market Analysis of Pneumococcal Vaccine. Further deep in this chapter, you will be able to review Europe Pneumococcal Vaccine Market Split by various segments and Country Split.
Chapter 3 Europe Market Analysis
-
3.1 Europe Pneumococcal Vaccine Market Size 2021 - 2033
-
3.1.1 Europe Pneumococcal Vaccine Market Size By Country 2021 - 2033
-
3.1.2 Europe Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
3.1.2.1 Europe Synflorix Market Size
-
3.1.2.2 Europe Pediatric Market Size
-
3.1.2.3 Europe Adult Market Size
-
3.1.2.4 Europe Prevenar-13 Market Size
-
3.1.2.5 Europe Pediatric Market Size
-
3.1.2.6 Europe Adult Market Size
-
3.1.2.7 Europe PCV 13 (pipeline) Market Size
-
3.1.2.8 Europe Pediatric Market Size
-
3.1.2.9 Europe Adult Market Size
-
3.1.2.10 Europe V114 (Merck) Market Size
-
3.1.2.11 Europe Pediatric Market Size
-
3.1.2.12 Europe Adult Market Size
-
3.1.2.13 Europe PCV-20 (Pfizer) Market Size
-
3.1.2.14 Europe Pediatric Market Size
-
3.1.2.15 Europe Adult Market Size
-
3.1.2.16 Europe PCV-10 (SII) Market Size
-
3.1.2.17 Europe Pediatric Market Size
-
3.1.2.18 Europe Adult Market Size
-
3.1.2.19 Europe PPSV-23 Market Size
-
3.1.2.20 Europe Pediatric Market Size
-
3.1.2.21 Europe Adult Market Size
-
-
3.1.3 Europe Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
3.1.3.1 Europe Wholesalers (pharmacy channel) Market Size
-
3.1.3.2 Europe Specialized Companies Market Size
-
3.1.3.3 Europe Public Authorities Market Size
-
3.1.3.4 Europe Others Market Size
-
-
3.1.4 Europe Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
3.1.4.1 Europe Public Market Size
-
3.1.4.2 Europe Private Market Size
-
-
-
3.2 United Kingdom Market Size 2021 - 2033
-
3.2.1 United Kingdom Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
3.2.2 United Kingdom Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
3.2.3 United Kingdom Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
3.3 France Market Size 2021 - 2033
-
3.3.1 France Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
3.3.2 France Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
3.3.3 France Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
3.4 Germany Market Size 2021 - 2033
-
3.4.1 Germany Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
3.4.2 Germany Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
3.4.3 Germany Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
3.5 Italy Market Size 2021 - 2033
-
3.5.1 Italy Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
3.5.2 Italy Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
3.5.3 Italy Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
3.6 Russia Market Size 2021 - 2033
-
3.6.1 Russia Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
3.6.2 Russia Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
3.6.3 Russia Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
3.7 Spain Market Size 2021 - 2033
-
3.7.1 Spain Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
3.7.2 Spain Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
3.7.3 Spain Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
3.8 Sweden Market Size 2021 - 2033
-
3.8.1 Sweden Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
3.8.2 Sweden Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
3.8.3 Sweden Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
3.9 Denmark Market Size 2021 - 2033
-
3.9.1 Denmark Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
3.9.2 Denmark Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
3.9.3 Denmark Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
3.10 Netherlands Market Size 2021 - 2033
-
3.10.1 Netherlands Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
3.10.2 Netherlands Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
3.10.3 Netherlands Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
3.11 Switzerland Market Size 2021 - 2033
-
3.11.1 Switzerland Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
3.11.2 Switzerland Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
3.11.3 Switzerland Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
3.12 Belgium Market Size 2021 - 2033
-
3.12.1 Belgium Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
3.12.2 Belgium Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
3.12.3 Belgium Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
3.13 Rest of Europe Market Size 2021 - 2033
-
3.13.1 Rest of Europe Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
3.13.2 Rest of Europe Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
3.13.3 Rest of Europe Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
This chapter will help you gain Asia Pacific Market Analysis of Pneumococcal Vaccine. Further deep in this chapter, you will be able to review Asia Pacific Pneumococcal Vaccine Market Split by various segments and Country Split.
Chapter 4 Asia Pacific Market Analysis
-
4.1 Asia Pacific Pneumococcal Vaccine Market Size 2021 - 2033
-
4.1.1 Asia Pacific Pneumococcal Vaccine Market Size By Country 2021 - 2033
-
4.1.2 Asia Pacific Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
4.1.2.1 Asia Pacific Synflorix Market Size
-
4.1.2.2 Asia Pacific Pediatric Market Size
-
4.1.2.3 Asia Pacific Adult Market Size
-
4.1.2.4 Asia Pacific Prevenar-13 Market Size
-
4.1.2.5 Asia Pacific Pediatric Market Size
-
4.1.2.6 Asia Pacific Adult Market Size
-
4.1.2.7 Asia Pacific PCV 13 (pipeline) Market Size
-
4.1.2.8 Asia Pacific Pediatric Market Size
-
4.1.2.9 Asia Pacific Adult Market Size
-
4.1.2.10 Asia Pacific V114 (Merck) Market Size
-
4.1.2.11 Asia Pacific Pediatric Market Size
-
4.1.2.12 Asia Pacific Adult Market Size
-
4.1.2.13 Asia Pacific PCV-20 (Pfizer) Market Size
-
4.1.2.14 Asia Pacific Pediatric Market Size
-
4.1.2.15 Asia Pacific Adult Market Size
-
4.1.2.16 Asia Pacific PCV-10 (SII) Market Size
-
4.1.2.17 Asia Pacific Pediatric Market Size
-
4.1.2.18 Asia Pacific Adult Market Size
-
4.1.2.19 Asia Pacific PPSV-23 Market Size
-
4.1.2.20 Asia Pacific Pediatric Market Size
-
4.1.2.21 Asia Pacific Adult Market Size
-
-
4.1.3 Asia Pacific Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
4.1.3.1 Asia Pacific Wholesalers (pharmacy channel) Market Size
-
4.1.3.2 Asia Pacific Specialized Companies Market Size
-
4.1.3.3 Asia Pacific Public Authorities Market Size
-
4.1.3.4 Asia Pacific Others Market Size
-
-
4.1.4 Asia Pacific Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
4.1.4.1 Asia Pacific Public Market Size
-
4.1.4.2 Asia Pacific Private Market Size
-
-
-
4.2 China Pneumococcal Vaccine Market Size 2021 - 2033
-
4.2.1 China Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
4.2.2 China Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
4.2.3 China Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
4.3 Japan Pneumococcal Vaccine Market Size 2021 - 2033
-
4.3.1 Japan Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
4.3.2 Japan Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
4.3.3 Japan Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
4.4 Korea Pneumococcal Vaccine Market Size 2021 - 2033
-
4.4.1 Korea Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
4.4.2 Korea Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
4.4.3 Korea Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
4.5 India Pneumococcal Vaccine Market Size 2021 - 2033
-
4.5.1 India Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
4.5.2 India Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
4.5.3 India Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
4.6 Australia Pneumococcal Vaccine Market Size 2021 - 2033
-
4.6.1 Australia Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
4.6.2 Australia Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
4.6.3 Australia Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
4.7 Philippines Pneumococcal Vaccine Market Size 2021 - 2033
-
4.7.1 Philippines Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
4.7.2 Philippines Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
4.7.3 Philippines Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
4.8 Singapore Pneumococcal Vaccine Market Size 2021 - 2033
-
4.8.1 Singapore Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
4.8.2 Singapore Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
4.8.3 Singapore Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
4.9 Malaysia Pneumococcal Vaccine Market Size 2021 - 2033
-
4.9.1 Malaysia Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
4.9.2 Malaysia Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
4.9.3 Malaysia Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
4.10 Thailand Pneumococcal Vaccine Market Size 2021 - 2033
-
4.10.1 Thailand Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
4.10.2 Thailand Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
4.10.3 Thailand Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
4.11 Indonesia Pneumococcal Vaccine Market Size 2021 - 2033
-
4.11.1 Indonesia Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
4.11.2 Indonesia Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
4.11.3 Indonesia Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
4.12 Rest of APAC Pneumococcal Vaccine Market Size 2021 - 2033
-
4.12.1 Rest of APAC Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
4.12.2 Rest of APAC Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
4.12.3 Rest of APAC Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
This chapter will help you gain South America Market Analysis of Pneumococcal Vaccine. Further deep in this chapter, you will be able to review South America Pneumococcal Vaccine Market Split by various segments and Country Split.
Chapter 5 South America Market Analysis
-
5.1 South America Pneumococcal Vaccine Market Size 2021 - 2033
-
5.1.1 South America Pneumococcal Vaccine Market Size By Country 2021 - 2033
-
5.1.2 South America Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
5.1.2.1 South America Synflorix Market Size
-
5.1.2.2 South America Pediatric Market Size
-
5.1.2.3 South America Adult Market Size
-
5.1.2.4 South America Prevenar-13 Market Size
-
5.1.2.5 South America Pediatric Market Size
-
5.1.2.6 South America Adult Market Size
-
5.1.2.7 South America PCV 13 (pipeline) Market Size
-
5.1.2.8 South America Pediatric Market Size
-
5.1.2.9 South America Adult Market Size
-
5.1.2.10 South America V114 (Merck) Market Size
-
5.1.2.11 South America Pediatric Market Size
-
5.1.2.12 South America Adult Market Size
-
5.1.2.13 South America PCV-20 (Pfizer) Market Size
-
5.1.2.14 South America Pediatric Market Size
-
5.1.2.15 South America Adult Market Size
-
5.1.2.16 South America PCV-10 (SII) Market Size
-
5.1.2.17 South America Pediatric Market Size
-
5.1.2.18 South America Adult Market Size
-
5.1.2.19 South America PPSV-23 Market Size
-
5.1.2.20 South America Pediatric Market Size
-
5.1.2.21 South America Adult Market Size
-
-
5.1.3 South America Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
5.1.3.1 South America Wholesalers (pharmacy channel) Market Size
-
5.1.3.2 South America Specialized Companies Market Size
-
5.1.3.3 South America Public Authorities Market Size
-
5.1.3.4 South America Others Market Size
-
-
5.1.4 South America Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
5.1.4.1 South America Public Market Size
-
5.1.4.2 South America Private Market Size
-
-
-
5.2 Brazil Pneumococcal Vaccine Market Size 2021 - 2033
-
5.2.1 Brazil Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
5.2.2 Brazil Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
5.2.3 Brazil Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
5.3 Argentina Pneumococcal Vaccine Market Size 2021 - 2033
-
5.3.1 Argentina Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
5.3.2 Argentina Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
5.3.3 Argentina Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
5.4 Colombia Pneumococcal Vaccine Market Size 2021 - 2033
-
5.4.1 Colombia Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
5.4.2 Colombia Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
5.4.3 Colombia Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
5.5 Peru Pneumococcal Vaccine Market Size 2021 - 2033
-
5.5.1 Peru Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
5.5.2 Peru Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
5.5.3 Peru Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
5.6 Chile Pneumococcal Vaccine Market Size 2021 - 2033
-
5.6.1 Chile Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
5.6.2 Chile Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
5.6.3 Chile Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
5.7 Rest of South America Pneumococcal Vaccine Market Size 2021 - 2033
-
5.7.1 Rest of South America Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
5.7.2 Rest of South America Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
5.7.3 Rest of South America Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
This chapter will help you gain Middle East and Africa Market Analysis of Pneumococcal Vaccine. Further deep in this chapter, you will be able to review Middle East and Africa Pneumococcal Vaccine Market Split by various segments and Country Split.
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Pneumococcal Vaccine Market Size 2021 - 2033
-
6.1.1 Middle East and Africa Pneumococcal Vaccine Market Size By Country 2021 - 2033
-
6.1.2 Middle East and Africa Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
6.1.2.1 Middle East and Africa Synflorix Market Size
-
6.1.2.2 Middle East and Africa Pediatric Market Size
-
6.1.2.3 Middle East and Africa Adult Market Size
-
6.1.2.4 Middle East and Africa Prevenar-13 Market Size
-
6.1.2.5 Middle East and Africa Pediatric Market Size
-
6.1.2.6 Middle East and Africa Adult Market Size
-
6.1.2.7 Middle East and Africa PCV 13 (pipeline) Market Size
-
6.1.2.8 Middle East and Africa Pediatric Market Size
-
6.1.2.9 Middle East and Africa Adult Market Size
-
6.1.2.10 Middle East and Africa V114 (Merck) Market Size
-
6.1.2.11 Middle East and Africa Pediatric Market Size
-
6.1.2.12 Middle East and Africa Adult Market Size
-
6.1.2.13 Middle East and Africa PCV-20 (Pfizer) Market Size
-
6.1.2.14 Middle East and Africa Pediatric Market Size
-
6.1.2.15 Middle East and Africa Adult Market Size
-
6.1.2.16 Middle East and Africa PCV-10 (SII) Market Size
-
6.1.2.17 Middle East and Africa Pediatric Market Size
-
6.1.2.18 Middle East and Africa Adult Market Size
-
6.1.2.19 Middle East and Africa PPSV-23 Market Size
-
6.1.2.20 Middle East and Africa Pediatric Market Size
-
6.1.2.21 Middle East and Africa Adult Market Size
-
-
6.1.3 Middle East and Africa Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
6.1.3.1 Middle East and Africa Wholesalers (pharmacy channel) Market Size
-
6.1.3.2 Middle East and Africa Specialized Companies Market Size
-
6.1.3.3 Middle East and Africa Public Authorities Market Size
-
6.1.3.4 Middle East and Africa Others Market Size
-
-
6.1.4 Middle East and Africa Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
6.1.4.1 Middle East and Africa Public Market Size
-
6.1.4.2 Middle East and Africa Private Market Size
-
-
-
6.2 Saudi Arabia Pneumococcal Vaccine Market Size 2021 - 2033
-
6.2.1 Saudi Arabia Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
6.2.2 Saudi Arabia Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
6.2.3 Saudi Arabia Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
6.3 Turkey Pneumococcal Vaccine Market Size 2021 - 2033
-
6.3.1 Turkey Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
6.3.2 Turkey Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
6.3.3 Turkey Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
6.4 Nigeria Pneumococcal Vaccine Market Size 2021 - 2033
-
6.4.1 Nigeria Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
6.4.2 Nigeria Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
6.4.3 Nigeria Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
6.5 UAE Pneumococcal Vaccine Market Size 2021 - 2033
-
6.5.1 UAE Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
6.5.2 UAE Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
6.5.3 UAE Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
6.6 Egypt Pneumococcal Vaccine Market Size 2021 - 2033
-
6.6.1 Egypt Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
6.6.2 Egypt Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
6.6.3 Egypt Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
6.7 South Africa Pneumococcal Vaccine Market Size 2021 - 2033
-
6.7.1 South Africa Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
6.7.2 South Africa Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
6.7.3 South Africa Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
6.8 GCC Countries Pneumococcal Vaccine Market Size 2021 - 2033
-
6.8.1 GCC Countries Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
6.8.2 GCC Countries Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
6.8.3 GCC Countries Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
-
6.9 Rest of MEA Pneumococcal Vaccine Market Size 2021 - 2033
-
6.9.1 Rest of MEA Pneumococcal Vaccine Market Size by Product Type Outlook: 2021 - 2033
-
6.9.2 Rest of MEA Pneumococcal Vaccine Market Size by Distribution Channel Outlook: 2021 - 2033
-
6.9.3 Rest of MEA Pneumococcal Vaccine Market Size by Sector Outlook: 2021 - 2033
-
This chapter provides an in-depth analysis of the market share among key competitors of Pneumococcal Vaccine. The analysis highlights each competitor's position in the market, growth trends, and financial performance, offering insights into competitive dynamics, and emerging players.
Chapter 7 Competitor Analysis (Subject to Data Availability (Private Players))
-
7.1 Top Competitors Analysis
-
7.1.1 Top Players Ranking 2024
-
7.1.2 Global Pneumococcal Vaccine Market Revenue and Share by Key Players
(Subject to Data Availability (Private Players))
-
7.1.3 Industry Mergers and Acquisition Analysis
-
7.1.4 New Product Launch Analysis
-
-
7.2 Company Profile (Data Subject to Availability) Sample Format
-
7.2.1 Serum Institute of India Pvt. Ltd.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
7.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
7.2.1.2 Business Overview
-
7.2.1.3 Financials (Subject to data availability)
-
7.2.1.4 Product Types Specification
-
7.2.1.5 Business Strategy
-
7.2.1.6 S.W.O.TAnalysis
-
-
7.2.2 CSL
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
7.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
7.2.2.2 Business Overview
-
7.2.2.3 Financials (Subject to data availability)
-
7.2.2.4 Product Types Specification
-
7.2.2.5 Business Strategy
-
7.2.2.6 S.W.O.TAnalysis
-
-
7.2.3 Sanofi
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
7.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
7.2.3.2 Business Overview
-
7.2.3.3 Financials (Subject to data availability)
-
7.2.3.4 Product Types Specification
-
7.2.3.5 Business Strategy
-
7.2.3.6 S.W.O.TAnalysis
-
-
7.2.4 GSK plc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
7.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
7.2.4.2 Business Overview
-
7.2.4.3 Financials (Subject to data availability)
-
7.2.4.4 Product Types Specification
-
7.2.4.5 Business Strategy
-
7.2.4.6 S.W.O.TAnalysis
-
-
7.2.5 Merck & Co. Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
7.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
7.2.5.2 Business Overview
-
7.2.5.3 Financials (Subject to data availability)
-
7.2.5.4 Product Types Specification
-
7.2.5.5 Business Strategy
-
7.2.5.6 S.W.O.TAnalysis
-
-
7.2.6 Pfizer Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
7.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
7.2.6.2 Business Overview
-
7.2.6.3 Financials (Subject to data availability)
-
7.2.6.4 Product Types Specification
-
7.2.6.5 Business Strategy
-
7.2.6.6 S.W.O.TAnalysis
-
-
7.2.7 Walvax Biotechnology Co. Ltd
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
7.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
7.2.7.2 Business Overview
-
7.2.7.3 Financials (Subject to data availability)
-
7.2.7.4 Product Types Specification
-
7.2.7.5 Business Strategy
-
7.2.7.6 S.W.O.TAnalysis
-
-
7.2.8 Beijing Minhai Biotechnology Co. Ltd.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
7.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
7.2.8.2 Business Overview
-
7.2.8.3 Financials (Subject to data availability)
-
7.2.8.4 Product Types Specification
-
7.2.8.5 Business Strategy
-
7.2.8.6 S.W.O.TAnalysis
-
-
This chapter would comprehensively cover market drivers, trends, restraints, opportunities, and various in-depth analyses like industrial chain, PESTEL, Porter’s Five Forces, and ESG, among others. It would also include product life cycle, technological advancements, and patent insights.
Chapter 8 Qualitative Analysis (Subject to Data Availability)
-
8.1 Market Drivers
-
8.2 Market Restraints
-
8.3 Market Trends
-
8.4 Market Opportunity
-
8.5 Technological Road Map (Subject to Data Availability)
-
8.6 Product Life Cycle (Subject to Data Availability)
-
8.7 Consumer Preference Analysis
-
8.8 Market Attractiveness Analysis
-
8.9 PESTEL Analysis
-
8.9.1 Political Factors
-
8.9.2 Economic Factors
-
8.9.3 Social Factors
-
8.9.4 Technological Factors
-
8.9.5 Legal Factors
-
8.9.6 Environmental Factors
-
-
8.10 Industrial Chain Analysis (Subject to Data Availability)
-
8.10.1 Industry Chain Analysis
-
8.10.2 Manufacturing Cost Analysis
-
8.10.3 Supply Side Analysis
-
8.10.3.1 Raw Material Analysis
-
8.10.3.2 Raw Material Procurement Analysis
-
8.10.3.3 Raw Material Price Trend Analysis
-
-
-
8.11 Porter’s Five Forces Analysis
-
8.11.1 Bargaining Power of Suppliers
-
8.11.2 Bargaining Power of Buyers
-
8.11.3 Threat of New Entrants
-
8.11.4 Threat of Substitutes
-
8.11.5 Degree of Competition
-
-
8.12 Patent Analysis (Subject to Data Availability)
-
8.13 ESG Analysis
Segmentation Product Type Outlook: Analysis 2019 -2031, will provide market size split by Product Type Outlook:. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 9 Market Split by Product Type Outlook: Analysis 2021 - 2033
-
9.1 Synflorix
-
9.1.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Synflorix 2021 - 2033
-
-
9.2 Pediatric
-
9.2.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Pediatric 2021 - 2033
-
-
9.3 Adult
-
9.3.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Adult 2021 - 2033
-
-
9.4 Prevenar-13
-
9.4.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Prevenar-13 2021 - 2033
-
-
9.5 Pediatric
-
9.5.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Pediatric 2021 - 2033
-
-
9.6 Adult
-
9.6.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Adult 2021 - 2033
-
-
9.7 PCV 13 (pipeline)
-
9.7.1 Global Pneumococcal Vaccine Revenue Market Size and Share by PCV 13 (pipeline) 2021 - 2033
-
-
9.8 Pediatric
-
9.8.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Pediatric 2021 - 2033
-
-
9.9 Adult
-
9.9.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Adult 2021 - 2033
-
-
9.10 V114 (Merck)
-
9.10.1 Global Pneumococcal Vaccine Revenue Market Size and Share by V114 (Merck) 2021 - 2033
-
-
9.11 Pediatric
-
9.11.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Pediatric 2021 - 2033
-
-
9.12 Adult
-
9.12.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Adult 2021 - 2033
-
-
9.13 PCV-20 (Pfizer)
-
9.13.1 Global Pneumococcal Vaccine Revenue Market Size and Share by PCV-20 (Pfizer) 2021 - 2033
-
-
9.14 Pediatric
-
9.14.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Pediatric 2021 - 2033
-
-
9.15 Adult
-
9.15.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Adult 2021 - 2033
-
-
9.16 PCV-10 (SII)
-
9.16.1 Global Pneumococcal Vaccine Revenue Market Size and Share by PCV-10 (SII) 2021 - 2033
-
-
9.17 Pediatric
-
9.17.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Pediatric 2021 - 2033
-
-
9.18 Adult
-
9.18.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Adult 2021 - 2033
-
-
9.19 PPSV-23
-
9.19.1 Global Pneumococcal Vaccine Revenue Market Size and Share by PPSV-23 2021 - 2033
-
-
9.20 Pediatric
-
9.20.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Pediatric 2021 - 2033
-
-
9.21 Adult
-
9.21.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Adult 2021 - 2033
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Distribution Channel Outlook: Analysis 2021 - 2033
-
10.1 Wholesalers (pharmacy channel)
-
10.1.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Wholesalers (pharmacy channel) 2021 - 2033
-
-
10.2 Specialized Companies
-
10.2.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Specialized Companies 2021 - 2033
-
-
10.3 Public Authorities
-
10.3.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Public Authorities 2021 - 2033
-
-
10.4 Others
-
10.4.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Others 2021 - 2033
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Sector Outlook: Analysis 2021 - 2033
-
11.1 Public
-
11.1.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Public 2021 - 2033
-
-
11.2 Private
-
11.2.1 Global Pneumococcal Vaccine Revenue Market Size and Share by Private 2021 - 2033
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Pneumococcal Vaccine market
Chapter 12 Research Findings
-
12.1 Key Takeaways
-
12.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
12.3 Assumptions and Acronyms
Chapter 13 Research Methodology and Sources
-
13.1 Primary Data Collection
-
13.1.1 Steps for Primary Data Collection
-
13.1.1.1 Identification of KOL
-
-
13.1.2 Backward Integration
-
13.1.3 Forward Integration
-
13.1.4 How Primary Research Help Us
-
13.1.5 Modes of Primary Research
-
-
13.2 Secondary Research
-
13.2.1 How Secondary Research Help Us
-
13.2.2 Sources of Secondary Research
-
-
13.3 Data Validation
-
13.3.1 Data Triangulation
-
13.3.2 Top Down & Bottom Up Approach
-
13.3.3 Cross check KOL Responses with Secondary Data
-
-
13.4 Data Representation
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Market Timeline 2021 till 2033, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
Market Timeline 2021 till 2033, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
Research Methodology Implemented by Anushka Gore and Team
- 1 Data Gathering
- 1.1 Primary Research
- 1.1.1 Steps for Primary Data Collection
- 1.1.1.1 Identification of KOL
- 1.1.1.2 Backward Integration
- 1.1.1.3 Forward Integration
- 1.1.1.4 How Primary Research Help Us
- 1.1.1.5 Modes of Primary Research
- 1.1.1 Steps for Primary Data Collection
- 1.2 Secondary Research
- 1.2.1 How Secondary Research Help Us
- 1.2.2 Sources of Secondary Research
- 1.1 Primary Research
- 2 Data Validation
- 2.1 Cross check KOL Responses with Secondary Data
- 2.2 Top Down & Bottom Up Approach
- 2.3 Data Triangulation
- 3 Data Representation
Key Questions Answered By Pneumococcal Vaccine Market Report 2025
| Why Synflorix have a significant impact on Pneumococcal Vaccine market? |
| What are the key factors affecting the Synflorix and Pediatric of Pneumococcal Vaccine Market? |
| What is the CAGR/Growth Rate of Wholesalers (pharmacy channel) during the forecast period? |
| By type, which segment accounted for largest share of the global Pneumococcal Vaccine Market? |
| Which region is expected to dominate the global Pneumococcal Vaccine Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
